Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-19, Stock:NVS, The news for the past five days is as follows:
2019-02-11: NEWS1: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS2: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS3: Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?.NEWS4: The roots of “servant leadership” management culture date back to Hermann Hesse and a young Hillary Clinton.NEWS5: Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View.NEWS6: Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View.NEWS7: Incyte Down as FDA Extends Review Period of Jakafi for GVHD.NEWS8: Incyte Down as FDA Extends Review Period of Jakafi for GVHD.NEWS9: Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?.NEWS10: Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?.NEWS11: [$$] Big Pharma’s Big Cancer Hope Is Fizzling.
2019-02-12: NEWS1: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.
2019-02-13: NEWS1: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS2: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS3: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS4: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS5: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS6: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS7: Conatus (CNAT) Completes Enrollment in Phase II NASH Study.NEWS8: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS9: Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin.NEWS10: Top Research Reports for ExxonMobil, Merck & Danaher.NEWS11: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.NEWS12: Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100.
2019-02-14: NEWS1: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS2: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS3: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS4: The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia.NEWS5: The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia.NEWS6: The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia.NEWS7: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial.NEWS8: [$$] J&J and Novartis back cancer geneticist’s immunotherapy start-up.
2019-02-15: NEWS1: U.S. Medicare plans to track CAR-T cancer therapy outcomes.NEWS2: Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc..NEWS3: Medicare would cover CAR-T therapies under new CMS proposal.NEWS4: What Are the Key Growth Drivers for GlaxoSmithKline in 2019?.

Answer: Rise